Anonymous
Guest
Anonymous
Guest
This thread should be scrapped! There might be 5 rep comments on the entire thread, and the rest are bottom feeder investors fishing for info.
No, keep it on! By all means! As the performance is shown to be poor, it's going to be entertaining to read the contorted and twisted explanations about what went wrong. Combined with all the coming teleconferences, action plans, activity spreadsheets, etc. this is going to be a sight to see.
Not clear who F'd this up, but it's a mess already!
No, keep it on! By all means! As the performance is shown to be poor, it's going to be entertaining to read the contorted and twisted explanations about what went wrong. Combined with all the coming teleconferences, action plans, activity spreadsheets, etc. this is going to be a sight to see.
Oleptro
-no real side effects
-fast acting
-better sleep (Huge with patients - lots of good feedback)
Overal Warm reception drug sales will continue to build. I am very impressed with the number of scripts being written.
Insignificant products buzz like dying flies while great products shout while capturing share and producing revenue.
That's just dumb, at the time you wrote this there was no rx data available and reps hadn't been in field.
Tried to tell you... this thread is mostly Labo penny stock investors BS'ing and fishing for info.
The first full month of IMS data is available this morning and Oleptro is...let me look here...I'm still looking...hang on a second...be patient...Oh, I see the problem here. Not enough NRX volume to register.
The first full month of IMS data is available this morning and Oleptro is...let me look here...I'm still looking...hang on a second...be patient...Oh, I see the problem here. Not enough NRX volume to register.
Seriously , how bad is it? I almost took a job with this contract. Should I be happy I didn't? Serious replies only. Thanks
Really? That's odd. The company stated that they're pleased with the launch. NRX data below the IMS thresh hold definitely doesn't align with that statement.